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Abstract: With the abundant number of articles published in lung
cancer, it has become very difficult to stay updated. After a search
through variety of medical journal for articles published between
March and June 2010, we selected the studies considered to have the
greatest relevance for oncologists involved in the treatment of lung
cancer. The nine selected studies covered a broad range of topics
including possible hormonal role in the development of lung ade-
nocarcinoma, lung cancer in never smokers, stereotactic radiother-
apy for early-stage lung cancer, prognostic role of pleural lavage
cytology, neoadjuvant chemotherapy for operable lung cancer,
maintenance erlotinib, use of erlotinib after gefitinib, comparison of
the two epidermal growth factor receptor tyrosine kinase inhibitors,
and risk of central nervous system relapse in patients treated with
epidermal growth factor receptor tyrosine kinase inhibitors.
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(J Thorac Oncol. 2011;6: 223–226)
RISK OF SECOND PRIMARY CANCER
ACCORDING TO HISTOLOGIC TYPE OF
NON-SMALL CELL LUNG CANCER
A Possible Etiological Role for Hormones in
Lung Adenocarcinoma
An international multicenter study involving 13 cancer
registries from Canada, Australia, Singapore, and several
European countries evaluated the occurrence of second pri-
mary cancers (SPCs) in patients with first primary lung
cancer diagnosed between 1943 and 2000.1 Lung cancer
subtypes were subdivided into squamous cell carcinoma,
small cell lung carcinoma, and adenocarcinoma excluding
bronchioloalveolar histology. Among the 258,559 patients
identified with 411,702 person-years, 5383 (2.08%) devel-
oped SPCs with an excess risk of 36% for women and 25%
for men. In both men and women, there was a strong asso-
ciation between smoking-associated SPC and all three lung
cancer subtypes. In contrast, the association with nonsmok-
ing-related SPCs was observed only in women with adeno-
carcinoma and men with either adenocarcinoma or small
cell lung carcinoma. Among the nonsmoking-related
SPCs, the most significant associations with primary lung
adenocarcinoma were breast and thyroid malignancies in
women and prostate cancer in men. The risk for second
primary breast cancer was higher in women with diagnosis of
lung adenocarcinoma at younger age. The increased risk of
second primary tumors in the breast or prostate suggests a
possible role of hormones in the development of lung ade-
nocarcinoma.
LUNG CANCER IN NEVER SMOKERS
The Search for Other Culprits
The etiology lung cancer in patients without previous
exposure to tobacco remains unclear in the majority of cases.
A recent genome-wide study was conducted to identify the
common genetic variations associated with an increased risk
for lung cancer in this patient population.2 Never smokers,
identified as less than 100 cigarettes lifetime smoking, were
identified from four major academic U.S. centers. Among the
44 candidate single-nucleotide polymorphisms identified in
the first stage of the study and tested in two external datasets,
rs2352028 and rs2352029 were replicated in the second
stage, and rs2352028 was replicated in the third stage. It is
estimated that rs2352028 may be responsible for more than
10% of lung cancer cases in never smokers. Both single-
nucleotide polymorphisms are located at the intron 5 of
GPC5 at 13q31.3, a member of the glypican family involved
in the regulation of cell division and proliferation. Therefore,
the genetic locus at 13q31.3 that regulates the expression of
GPC5 may be associated with the development of lung
cancer in never smokers. Obviously, more studies are needed
to confirm these observations.
STEREOTACTIC BODY RADIATION THERAPY
FOR INOPERABLE EARLY-STAGE LUNG
CANCER
The Fight for Local Control
Primary tumor control with conventional external beam
radiotherapy in patients who are medically inoperable is
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generally poor, with a 60 to 70% failure and 3-year survival
of less than 35%. In an attempt to improve the outcomes
through better local control, the Radiation Therapy Oncology
Group 0236 conducted a multicenter trial to evaluate the role
of stereotactic body radiation therapy in this patient popula-
tion.3 In this phase II study, 55 patients with non-small cell
lung cancer (NSCLC) stage T1N0M0 (80%) or T2N0M0
(20%) measuring less than 5 cm were treated with 54 Gy in
three fractions of 18 Gy administered within 14 days. Patients
were evaluated every 3 months for the first 2 years and every
6 months from years 2 to 4. The primary end point was the
2-year primary tumor control. The treatment was very well
tolerated with grade 3 and grade 4 toxicities observed in
seven (12.7%) and two (3.6%) patients, respectively. Overall
response rate was 89% with 28 patients (51%) achieving
complete response. The 3-year primary tumor control rate
was 97.6%, with only one patient, with stage IB, developed
recurrence at the primary site. Two additional patients devel-
oped regional failure for a locoregional control of 87.2%.
Among the 12 distant relapses (22%), eight occurred within
the first 24 months. Distant relapses were predictably more
common in patients with stage IB than those with IA NSCLC
(47.0% versus 14.7%).
PLEURAL LAVAGE CYTOLOGY IN RESECTED
NSCLC
An Overlooked Prognostic Factor
Pleural lavage cytology (PLC) is a simple and inexpen-
sive procedure consisting of the microscopic evaluation of
cells obtained after saline instillation of the chest cavity
during NSCLC surgery. An international individual patient
data meta-analysis has been reported recently.4 Among the
8763 patients from 11 centers, 511 (5.8%) had documented
positive PLC, with 477 of them having complete staging
information. Positive PLC status was an independent predic-
tor for worse survival in multivariate analysis (hazard ratio
[HR], 1.46; p  0.001). The net effect of positive PLC using
an exploratory statistical modeling was an upstage of T status
by a single-numerical T category up to T4. At this time, the
benefit from adjuvant chemotherapy in patients with early T
stage and positive PLC is unclear.
NEOADJUVANT CHEMOTHERAPY FOR NSCLC
Still Not Standard of Care
Based on encouraging results from a phase II study, the
Southwest Oncology Group trial S9900 randomly assigned
patients with stages IB to IIIA NSCLC to surgery alone or
three cycles of neoadjuvant carboplatin plus paclitaxel fol-
lowed by surgical resection.5 This study had to be closed
prematurely when it became evident that adjuvant chemo-
therapy improves survival in patients with resected stages I to
III NSCLC, and surgery alone arm (control) was no longer
deemed ethical. Among the eligible patients, 168 were as-
signed to surgery alone and 169 to preoperative therapy.
Seventy-nine percent of patients received all three cycles of
neoadjuvant therapy. With a median follow-up of 64 months,
the median and 5-year progression-free survival (PFS) rates
were 20 months and 33%, respectively, for the surgery alone
and 33 months and 42%, respectively, in the neoadjuvant
group (HR, 0.80; p  0.10). Median and 5-year overall
survival (OS) rates were 41 months and 41%, respectively, in
the surgery only and 62 months and 50%, respectively, in the
neoadjuvant group (HR, 0.79; p  0.11). Despite a 9%
absolute improvement in the 5-year OS, which was very
similar to the benefit observed in adjuvant trials, the differences
did not reach statistical significance, most likely due to a small
sample size. Taken together, results from this study along with
results of a recent meta-analysis from 13 randomized clinical
trials showing improved OS from neoadjuvant chemotherapy
compared with surgery alone (HR 0.84; p  0.0001)6 and
several published studies on adjuvant chemotherapy, there is a
strong evidence for the use of systemic chemotherapy in patients
with resected NSCLC. Although the optimal timing of chemo-
therapy may need more clarification, the supporting data are
stronger on the use of postoperative chemotherapy.
MAINTENANCE ERLOTINIB
One More Option for the Believers!
Until recently, the standard therapy for patients with
advanced-stage NSCLC has been to administer from four to
six cycles of chemotherapy followed by a rest until evidence
of progressive disease.7 This recommendation, however, has
been recently challenged with the preliminary results of trials
showing benefit from switch maintenance, defined as the
initiation of an agent not included in the first four to six cycles
of therapy in patients without disease progression. Cappuzzo
et al.8 reported the final results of the randomized phase 3
Sequential Tarceva in Unresectable NSCLC. This large mul-
ticenter study accrued 1949 patients previously treated with
platinum-based doublets from 110 sites in 26 countries. The
primary end point was PFS. Among the 889 patients with
clinical benefit from first-line chemotherapy, 438 were ran-
domized to erlotinib and 451 to placebo. Treatment with
erlotinib was well tolerated, with the most common toxicities,
as expected, being rash and diarrhea. With a median fol-
low-up of 11.5 months, the PFS was significantly prolonged
in the erlotinib arm (12.3 versus 11.1 weeks; HR, 0.69; p 
0.0001). This benefit was statistically significant in patients
with either epidermal growth factor receptor (EGFR) activat-
ing mutations (HR, 0.1; p  0.001) or wild type (HR, 0.78;
p 0.018). Similar to PFS, OS was also prolonged with
erlotinib (12 versus 11 months; HR, 0.81; p  0.008). The
PFS benefit was observed in all categories of patients with
stage IV disease regardless of age group, gender, ethnicity,
smoking status, performance status, and histology. Therefore,
unlike the pemetrexed, which has a benefit limited to patients
with nonsquamous histology,9 a modest clinical benefit with
maintenance erlotinib was achieved in patients with all his-
tologic subtypes.
ERLOTINIB AFTER GEFITINIB
An Option for Some!
Small studies evaluating the use of erlotinib after pro-
gression through gefitinib reported conflicting results. To
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further define this approach, a pooled analysis of 106 patients
from 11 studies was conducted.10 The studies ranged in size
from 1 to 23 patients and comprised five case reports with 11
patients, three retrospective studies with 43 patients, and
three prospective studies with 52 patients. Prior response to
gefitinib was 43.4% with an additional 27% achieving stable
disease (SD). Eleven patients (9.9%) achieved partial re-
sponse and 20 (18.9%) had SD for a disease control rate of
29.2% on subsequent erlotinib. The only significant predic-
tors for disease control from erlotinib were SD and PFS
greater than 6 months on prior gefitinib. EGFR mutation
status did not predict outcomes in this setting. Response rates
and disease stabilization were 6.3% and 31.3%, respectively,
in the 32 patients with EGFR mutation and 8.7% and 13.1%,
respectively, in the 23 patients with wild-type EGFR (p 
0.81). In summary, this pooled analysis suggested that erlo-
tinib should be considered in patients with prior benefit from
gefitinib, regardless of EGFR mutation status.
GEFITINIB VERSUS ERLOTINIB IN NSCLC
Distinct but Not Different
Despite similar response rates, SD, and survival
achieved with either gefitinib or erlotinib, only the latter
showed improved survival compared with placebo in a ran-
domized phase III trial.11,12 There are no data comparing
these two agents head to head in NSCLC. Therefore, Kim et
al.13 conducted a retrospective study at the Samsung Medical
Center in Korea to address this issue. Between January 2006
and December 2008, 210 previously treated patients with
advanced-stage NSCLC received gefitinib and 257 received
erlotinib. To minimize the heterogeneity between the groups,
171 patients from each treatment group were matched ac-
cording to gender, Eastern Cooperative Oncology Group
performance status, histology, and smoking history. There
were no significant differences between gefitinib and erlotinib
regarding overall response rate (38% for gefitinib versus
32.2% for erlotinib), disease control rate (63.2% versus
64.9%, p 0.67), median OS from starting either agent (12.6
versus 12.1 months, p  0.97), or PFS (4.6 versus 2.7
months, p  0.06). Similarly, there were no differences in
outcomes between the two agents according to the predefined
subgroup of patients. Despite the limitations from this study,
including the retrospective nature with arbitrary paired
matching according to four variables and the lack of EGFR
mutation status, this study provided further evidence to sup-
port the similar efficacy between gefitinib and erlotinib.
CENTRAL NERVOUS SYSTEM FAILURE IN
PATIENTS TREATED WITH EGFR TYROSINE
KINASE INHIBITORS
A Note of Caution
Since there have been anecdotal reports of central
nervous system (CNS) metastases in patients achieving pro-
longed response to EGFR tyrosine kinase inhibitors (TKIs),
Lee et al.14 conducted a retrospective study to investigate the
risk of CNS failure in patients achieving benefit from either
gefitinib or erlotinib. There were 29 patients with previously
treated CNS metastases, including 15 on the clinical benefit
group and 14 in the nonclinical benefit group. Clinical benefit
was defined as lack of progressive disease during the first 90
days of therapy and was present in 127 (54.7%) of the 232
eligible patients. For all patients combined, the most common
sites of progression were lung (63%) and CNS (16%). The
incidence of CNS progression was higher in patients with
clinical benefit compared with those without clinical benefit,
either as overall (26% versus 4%, p 0.001) or isolated CNS
progression without systemic failure (13% versus 1%, p 
0.001). In multivariate analysis, the only independent factor
for CNS metastases was the clinical benefit from TKIs (HR,
10.9; p  0.01). The authors provided four possible expla-
nations for their finding including late development of brain
metastases favored by prolonged therapy, higher frequency of
EGFR mutation in brain metastases with possible tropism of
these tumors to the CNS possibly mediated by signal trans-
ducer and activator of transcription-3 incomplete CNS pen-
etration of the drug, and inherited or acquired resistance to
EGFR TKIs by CNS metastatic clones. Regardless of the
mechanism, if the increased incidence of CNS metastases in
patients achieving benefit from EGFR TKIs is confirmed in
prospective studies, there may be a role for more intense
surveillance of the brain, with more frequent imaging studies
during the therapy to provide early diagnosis and therapy for
this debilitating metastatic site.
REFERENCES
1. Chuang S, Sce´lo G, Lee YC, et al. Risks of second primary cancer
among patients with major histological types of lung cancers in both
men and women. Br J Cancer 2010;102:1190–1195.
2. Li Y, Sheu C, Ye Y, et al. Genetic variants and risk of lung cancer in
never smokers: a genome-wide association study. Lancet Oncol 2010;
11:321–330.
3. Timmerman R, Paulus R, Galvin J, et al. Stereotactic body radiation
therapy for inoperable early stage lung cancer. JAMA 2010;303:1070–
1076.
4. Lim E, Clough R, Goldstraw P, et al. Impact of positive pleural lavage
cytology on survival in patients having lung resection for non-small-cell
lung cancer: an international individual patient data meta-analysis.
J Thorac Cardiovasc Surg 2010;139:1441–1446.
5. Pisters KM, Vallie`res E, Crowley JJ, et al. Surgery with or without
preoperative paclitaxel and carboplatin in early-stage non-small-cell
lung cancer: Southwest Oncology Group Trial S9900, an intergroup,
randomized, phase III trial. J Clin Oncol 2010;28:1843–1849.
6. Song WA, Zhou NK, Wang W, et al. Survival benefit of neoadjuvant
chemotherapy in non-small cell lung cancer: an updated meta-analysis of
13 randomized control trials. J Thorac Oncol 2010;5:510–516.
7. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical
Oncology treatment of unresectable non-small-cell lung cancer guide-
line: update 2003. J Clin Oncol 2004;22:330–353.
8. Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance
treatment in advanced non-small-cell lung cancer: a multicentre, ran-
domised, placebo-controlled phase 3 study. Lancet Oncol 2010;11:521–
529.
9. Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed
plus best supportive care versus placebo plus best supportive care for
non-small-cell lung cancer: a randomised, double-blind, phase 3 study.
Lancet 2009;374:1432–1440.
10. Kaira K, Naito T, Takahashi T, et al. Pooled analysis of the reports of
erlotinib after failure of gefitinib for non-small cell lung cancer. Lung
Cancer 2010;68:99–104.
Journal of Thoracic Oncology • Volume 6, Number 1, January 2011 Best of the Month
Copyright © 2010 by the International Association for the Study of Lung Cancer 225
11. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in
previously treated patients with refractory advanced non-small-cell lung
cancer: results from a randomised, placebo-controlled, multicentre study
(Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527–1537.
12. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in
previously treated non-small-cell lung cancer. N Engl J Med 2005;353:
123–132.
13. Kim ST, Lee J, Kim JH, et al. Comparison of gefitinib versus erlotinib
in patients with nonsmall cell lung cancer who failed previous chemo-
therapy. Cancer 2010;116:3025–3033.
14. Lee YJ, Choi HJ, Kim SK, et al. Frequent central nervous system failure
after clinical benefit with epidermal growth factor receptor tyrosine
kinase inhibitors in Korean patients with nonsmall-cell lung cancer.
Cancer 2010;116:1336–1343.
Morgensztern and Govindan Journal of Thoracic Oncology • Volume 6, Number 1, January 2011
Copyright © 2010 by the International Association for the Study of Lung Cancer226
